Latest Advances in Lung Cancer Research

Merck pulls Keytruda for SCLC. Pharmaceutical company, Merck announced plans to pull Ketruda for SCLC due to disappointing results from Phase III trial.

Antibody hinders EGFR lung cancer: Johnson&Johnson’s drug shows succes in hindering tumor growth in 74% of lung cancer patients with EGFR mutations.

Study defines SCLC subtypes. Study provides a transformative new system to define four major groups of small-cell lung cancer.

How biomarkers impact treatment decisions. Biomarkers indicate that a patient’s immune system knows that the tumor is there.

Genetics influence SCLC risk: The genetic factors that influence small cell lung cancer risk have not received a great deal of attention from scientists.

Exploring saliva in early lung cancer detection: UCLA School of Dentistry researchers are looking at saliva for its diagnostic possibilities.

A sizable body of research has long shown racial disparities in treatment and survival between Black and White patients with lung cancer.

Lung cancer stigma negatively impacts the clinical care and outcomes of those diagnosed, resulting in enduring disparities.

Lung cancer in never smokers is becoming more prominent – especially in women. 12% of U.S. lung cancer patients are never-smokers and it is increasing.

FDA approves new liquid biopsy tests using NGS to detect tumor DNA, aiding targeted cancer therapy selection.

Lung cancer screenings down due to COVID. Drop in lung cancer screenings due to canceled or postponed services has led to worse patient outcomes.